Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression

Thomas D. Geracioti, Linda L. Carpenter, Michael J. Owens, Dewleen G. Baker, Nosakhare N. Ekhator, Paul S. Horn, Jeffrey R. Strawn, Gerard Sanacora, Becky Kinkead, Lawrence H. Price, Charles Nemeroff

Research output: Contribution to journalArticle

Abstract

Objective: The authors tested the hypothesis that concentrations of the pain-transmitting neuropeptide substance P are elevated in the CSF of patients with major depression or posttraumatic stress disorder (PTSD), which have overlapping symptoms. The authors also sought to determine if CNS substance P concentrations change on provocation of symptoms in PTSD patients. Method: The authors measured CSF substance P concentrations in medication-free patients with either major depression or PTSD and in healthy comparison subjects. Next, using a within-subject, cross-over design, the authors sampled CSF for 6 hours through an indwelling subarachnoid catheter in PTSD patients before, during, and after exposure to a 60-minute traumatic or neutral videotape stimulus. Results: Both depressed and PTSD patients had significantly elevated basal CSF substance P concentrations. In the challenge study, marked increases in CSF substance P concentrations were found only after precipitation of PTSD symptoms. CSF substance P concentrations increased by 169% and 90.6% of baseline levels at 10 and 70 minutes, respectively, after the start of the traumatic videotape but changed by only 1.1% and -8.1% of baseline levels 10 and 70 minutes after the start of the neutral videotape. Conclusions: These results suggest that elevated CNS substance P concentrations are involved in both major depression and PTSD. The marked increase in CSF substance P concentrations during and after the symptom-provoking stimulus, but not after the neutral stimulus, implicates CNS release of substance P in the mechanism of acute PTSD symptoms. These data also reveal that CNS substance P responds acutely to psychological stress in humans.

Original languageEnglish
Pages (from-to)637-643
Number of pages7
JournalAmerican Journal of Psychiatry
Volume163
Issue number4
DOIs
StatePublished - Apr 1 2006
Externally publishedYes

Fingerprint

Substance P
Post-Traumatic Stress Disorders
Cerebrospinal Fluid
Depression
Videotape Recording
Stress Disorders, Traumatic, Acute
Indwelling Catheters
Neuropeptides
Psychological Stress
Cross-Over Studies
Healthy Volunteers
Pain

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. / Geracioti, Thomas D.; Carpenter, Linda L.; Owens, Michael J.; Baker, Dewleen G.; Ekhator, Nosakhare N.; Horn, Paul S.; Strawn, Jeffrey R.; Sanacora, Gerard; Kinkead, Becky; Price, Lawrence H.; Nemeroff, Charles.

In: American Journal of Psychiatry, Vol. 163, No. 4, 01.04.2006, p. 637-643.

Research output: Contribution to journalArticle

Geracioti, TD, Carpenter, LL, Owens, MJ, Baker, DG, Ekhator, NN, Horn, PS, Strawn, JR, Sanacora, G, Kinkead, B, Price, LH & Nemeroff, C 2006, 'Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression', American Journal of Psychiatry, vol. 163, no. 4, pp. 637-643. https://doi.org/10.1176/appi.ajp.163.4.637
Geracioti, Thomas D. ; Carpenter, Linda L. ; Owens, Michael J. ; Baker, Dewleen G. ; Ekhator, Nosakhare N. ; Horn, Paul S. ; Strawn, Jeffrey R. ; Sanacora, Gerard ; Kinkead, Becky ; Price, Lawrence H. ; Nemeroff, Charles. / Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. In: American Journal of Psychiatry. 2006 ; Vol. 163, No. 4. pp. 637-643.
@article{50532fd7559d48a19807b0c0c863df74,
title = "Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression",
abstract = "Objective: The authors tested the hypothesis that concentrations of the pain-transmitting neuropeptide substance P are elevated in the CSF of patients with major depression or posttraumatic stress disorder (PTSD), which have overlapping symptoms. The authors also sought to determine if CNS substance P concentrations change on provocation of symptoms in PTSD patients. Method: The authors measured CSF substance P concentrations in medication-free patients with either major depression or PTSD and in healthy comparison subjects. Next, using a within-subject, cross-over design, the authors sampled CSF for 6 hours through an indwelling subarachnoid catheter in PTSD patients before, during, and after exposure to a 60-minute traumatic or neutral videotape stimulus. Results: Both depressed and PTSD patients had significantly elevated basal CSF substance P concentrations. In the challenge study, marked increases in CSF substance P concentrations were found only after precipitation of PTSD symptoms. CSF substance P concentrations increased by 169{\%} and 90.6{\%} of baseline levels at 10 and 70 minutes, respectively, after the start of the traumatic videotape but changed by only 1.1{\%} and -8.1{\%} of baseline levels 10 and 70 minutes after the start of the neutral videotape. Conclusions: These results suggest that elevated CNS substance P concentrations are involved in both major depression and PTSD. The marked increase in CSF substance P concentrations during and after the symptom-provoking stimulus, but not after the neutral stimulus, implicates CNS release of substance P in the mechanism of acute PTSD symptoms. These data also reveal that CNS substance P responds acutely to psychological stress in humans.",
author = "Geracioti, {Thomas D.} and Carpenter, {Linda L.} and Owens, {Michael J.} and Baker, {Dewleen G.} and Ekhator, {Nosakhare N.} and Horn, {Paul S.} and Strawn, {Jeffrey R.} and Gerard Sanacora and Becky Kinkead and Price, {Lawrence H.} and Charles Nemeroff",
year = "2006",
month = "4",
day = "1",
doi = "10.1176/appi.ajp.163.4.637",
language = "English",
volume = "163",
pages = "637--643",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "4",

}

TY - JOUR

T1 - Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression

AU - Geracioti, Thomas D.

AU - Carpenter, Linda L.

AU - Owens, Michael J.

AU - Baker, Dewleen G.

AU - Ekhator, Nosakhare N.

AU - Horn, Paul S.

AU - Strawn, Jeffrey R.

AU - Sanacora, Gerard

AU - Kinkead, Becky

AU - Price, Lawrence H.

AU - Nemeroff, Charles

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Objective: The authors tested the hypothesis that concentrations of the pain-transmitting neuropeptide substance P are elevated in the CSF of patients with major depression or posttraumatic stress disorder (PTSD), which have overlapping symptoms. The authors also sought to determine if CNS substance P concentrations change on provocation of symptoms in PTSD patients. Method: The authors measured CSF substance P concentrations in medication-free patients with either major depression or PTSD and in healthy comparison subjects. Next, using a within-subject, cross-over design, the authors sampled CSF for 6 hours through an indwelling subarachnoid catheter in PTSD patients before, during, and after exposure to a 60-minute traumatic or neutral videotape stimulus. Results: Both depressed and PTSD patients had significantly elevated basal CSF substance P concentrations. In the challenge study, marked increases in CSF substance P concentrations were found only after precipitation of PTSD symptoms. CSF substance P concentrations increased by 169% and 90.6% of baseline levels at 10 and 70 minutes, respectively, after the start of the traumatic videotape but changed by only 1.1% and -8.1% of baseline levels 10 and 70 minutes after the start of the neutral videotape. Conclusions: These results suggest that elevated CNS substance P concentrations are involved in both major depression and PTSD. The marked increase in CSF substance P concentrations during and after the symptom-provoking stimulus, but not after the neutral stimulus, implicates CNS release of substance P in the mechanism of acute PTSD symptoms. These data also reveal that CNS substance P responds acutely to psychological stress in humans.

AB - Objective: The authors tested the hypothesis that concentrations of the pain-transmitting neuropeptide substance P are elevated in the CSF of patients with major depression or posttraumatic stress disorder (PTSD), which have overlapping symptoms. The authors also sought to determine if CNS substance P concentrations change on provocation of symptoms in PTSD patients. Method: The authors measured CSF substance P concentrations in medication-free patients with either major depression or PTSD and in healthy comparison subjects. Next, using a within-subject, cross-over design, the authors sampled CSF for 6 hours through an indwelling subarachnoid catheter in PTSD patients before, during, and after exposure to a 60-minute traumatic or neutral videotape stimulus. Results: Both depressed and PTSD patients had significantly elevated basal CSF substance P concentrations. In the challenge study, marked increases in CSF substance P concentrations were found only after precipitation of PTSD symptoms. CSF substance P concentrations increased by 169% and 90.6% of baseline levels at 10 and 70 minutes, respectively, after the start of the traumatic videotape but changed by only 1.1% and -8.1% of baseline levels 10 and 70 minutes after the start of the neutral videotape. Conclusions: These results suggest that elevated CNS substance P concentrations are involved in both major depression and PTSD. The marked increase in CSF substance P concentrations during and after the symptom-provoking stimulus, but not after the neutral stimulus, implicates CNS release of substance P in the mechanism of acute PTSD symptoms. These data also reveal that CNS substance P responds acutely to psychological stress in humans.

UR - http://www.scopus.com/inward/record.url?scp=33646452520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646452520&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.163.4.637

DO - 10.1176/appi.ajp.163.4.637

M3 - Article

C2 - 16585438

VL - 163

SP - 637

EP - 643

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 4

ER -